|
|
|
|
|
BOND-003 Trial Results for BCG Unresponsive Non-Muscle Invasive Bladder Cancer
|
|
Mark Tyson II, MD, MPH
|
| Zachary Klaassen hosts Mark Tyson to discuss the groundbreaking BOND-003 trial, evaluating cretostimogene monotherapy for BCG-unresponsive non-muscle invasive bladder cancer, which demonstrates sustained, durable complete responses in high-risk patients.
|
|
|
|
|
|
|
|
|
|
|
|
| CG Oncology Announces Bond-003 Topline Results
|
| Press Release
|
| Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.
|
|
|
|
|
|
| Topline Results from BOND-003: A Phase-3 Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High-Risk BCG-Unresponsive NMIBC with CIS |
| Mark Tyson II, MD, MPH |
| Mark Tyson presented results from the BOND-003 trial evaluating cretostimogene grenadenorepvec for BCG-unresponsive NMIBC with CIS. The study demonstrated a 74.5% complete response (CR) rate, with durable responses exceeding 27 months and 64% of responders maintaining CR at 12 months. Safety data showed no grade ≥3 adverse events, and the treatment was well-tolerated, offering a promising bladder-sparing therapy for NMIBC patients. |
|
|
|
|
|
| A Personalized and Pragmatic Approach to (P)rehabilitation for Patients with Bladder Cancer |
| Sarah Psutka, MD, MSc |
| Sarah Psutka's SUO 2024 presentation emphasized the importance of prehabilitation for bladder cancer patients, focusing on personalized strategies to improve treatment readiness, recovery outcomes, and quality of life. She highlighted physical, nutritional, and cognitive prehabilitation, supported by evidence like the ENHANCE trial and tools such as the CARE-GA and SPPB, advocating for universal, scalable, and multidisciplinary approaches to optimize patient care. |
|
|
|
|
|
|
|
|
|
|
| Precision in Urothelial Carcinoma: Overarching Theme 2 – ctDNA-Based Clinical Decision-Making in Urothelial Cancer: What Do We Know in 2024? |
| Matthew Galsky, MD |
| Matthew Galsky discussed ctDNA-based clinical decision-making in urothelial cancer, emphasizing its potential to refine perioperative systemic therapy by identifying patients who may benefit from adjuvant treatment. He highlighted the "double biomarker dilemma," which involves determining both the need for therapy and the likelihood of benefit. |
|
|
|
|
|
| The Evolution of First-Line Treatment for Metastatic Urothelial Cancer |
| Tracy Rose, MD, MPH |
| Tracy Rose detailed the evolution of first-line treatments for metastatic urothelial carcinoma (mUC). Historically dominated by platinum-based chemotherapies like gemcitabine-cisplatin and dose-dense MVAC, the field expanded to include immune checkpoint inhibitors (e.g., atezolizumab, pembrolizumab) for cisplatin-ineligible patients in 2017. The 2020 JAVELIN Bladder 100 study introduced maintenance avelumab for improved survival post-chemotherapy. |
|
|
|
|
|
| Emerging Treatments and New Targets for Metastatic Urothelial Cancer |
| Vadim Koshkin, MD |
| Vadim Koshkin highlighted significant advances in metastatic urothelial carcinoma treatment, emphasizing antibody-drug conjugates like enfortumab vedotin and trastuzumab deruxtecan. Key targets include Nectin-4, HER2, Trop-2, and FGFR3, with novel drugs and combinations (e.g., EV + pembrolizumab) demonstrating impressive outcomes. Future directions focus on intensifying therapies early in the treatment course and exploring innovative combinations to build on recent progress. |
|
|
|
|
|
|
|
|
|
|
